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Background
Corticosteroids are active agents, which are especially
applicated orally in the dermatological emergency medi-
cine. Due to German anaphylaxis guidelines patients
emergency kit must contain a corticosteroid with a Pre-
dnisolone-equivalent of at least 100 mg. Due to different
reasons, a liquid corticosteroid is to be recommended.
At the present time, there is no comparable liquid
remedy available. The alternative is intravenously admi-
nistered prednisolone. Due to this reason, a new formula
is created by a research group of pharmacologists and
dermatologists. They are working close to the Pharma-
ceutical Laboratory of the New Prescription Formulatory
(NRF) in Germany, which is developing new formula-
tions, also the Prednisolone formula. The new formula
contains a Prednisolone-equivalent up to 500 milligrams
per 100 milliliters liquid agent.
Methods
We studied 60 patients, who came on an emergency
basis to our university hospital with severe acute or
chronic spontaneous urticaria and/or angioedema, half
of them including throat swallowing. We observed the
efficacy of the new prednisolone liquid in different con-
centrations as well as possible adverse events during the
course of the treatment in comparison to intravenously
administered prednisolone.
Results
Up to the dosage over 250 mg Prednisolone-equivalent
– similar to the intravenous therapy with the same
dosage – a fast reduction of the symptoms (less than 30
minutes) was realized in urticaria, angioedema and
throat swallowing comparable with the intravenous
injections. No adverse events occured.
Conclusions
This new Prednisolone formula is a new therapeutic
alternative rescue medication.
Published: 12 August 2011
doi:10.1186/2045-7022-1-S1-P107
Cite this article as: Staubach et al.: A new oral liquid formula including
high dose prednisolone. Clinical and Translational Allergy 2011 1(Suppl 1):
P107.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Department of Dermatology University Mainz, Mainz, Germany
Staubach et al. Clinical and Translational Allergy 2011, 1(Suppl 1):P107
http://www.ctajournal.com/content/1/S1/P107
© 2011 Staubach et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.